FDA regulatory actions in Q1 2025 include approval of Celltrion's denosumab biosimilars and Fast Track designation for CAR-T therapies targeting lupus, expanding treatment options for autoimmune conditions.
The global rheumatoid arthritis market is projected to grow from $28 billion in 2024 to $34.7 billion by 2035, with a CAGR of 1.97%, fueled by advancements in biologics and targeted therapies.
AnaptysBio's rosnilimab meets primary and secondary endpoints in Phase 2b rheumatoid arthritis trial, though efficacy appears similar to competitor peresolimab.